非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制药治疗的现状与挑战

Current Situation and Challenges of EGFR-TKI in Non-Small Cell Lung Cancer

过去十年,针对表皮生长因子受体(EGFR)的酪氨酸激酶抑制药(TKI)引领了非小细胞肺癌(NSCLC)治疗的精准医学之路,在晚期NSCLC的治疗中取得了重大突破。NSCLC的治疗理念已由以病理分型为基础的传统放射治疗、化学治疗转变为以分子分型为依据的精准治疗。优化第3代EGFR-TKI的管理,扩大EGFR-TKI的适应证,联合其他治疗提升疗效,探索耐药机制及应对策略都是EGFR-TKI面临的重要挑战。

Last decade,EGFR-TKI have led the way of precision medicine for NSCLC and have made significant breakthroughs in the treatment of advanced NSCLC.The treatment concept of NSCLC have changed from traditional chemoradiotherapy based on pathological type to precise treatment based on molecular type.Optimizing the management of the third generation of EGFR-TKI,expanding the indications of EGFR-TKI,improving efficacy with the combination of other treatments,exploring the mechanisms and strategies of drug resistance are significant challenges for EGFR-TKI.